Members Members Residents Job Board
Join Today Renew Your Membership Make A Donation
2001 Abstract: 561 Specific Targeting of Tumor Vasculature by DT-VEGF Fusion Protein Reduces Angiogenesis and Growth of Pancreatic Cancer

2001 Digestive Disease Week

# 561 Specific Targeting of Tumor Vasculature by DT-VEGF Fusion Protein Reduces Angiogenesis and Growth of Pancreatic Cancer
Hubert G. Hotz, Parkash S. Gill, Rizwan Masood, Birgit Hotz, Heinz J Buhr, Thomas Foitzik, Oscar J. Hines, Howard A. Reber, Los Angeles, CA, Berlin, Germany

Anti-angiogenesis is a novel treatment strategy for pancreatic cancer (PaCa). Activated endothelial cells of the tumor vasculature abundantly express receptors for vascular endothelial growth factor (VEGF), a key mediator of angiogenesis. The aim of the study was to specifically target and damage the vasculature of PaCa by fusing the VEGF isoform VEGF165 to diphtheria toxin (DT), which inhibits the protein synthesis of target cells.

Methods: VEGF165 fusion protein containing the enzymatic and translocation domains of DT was produced with GST in vector pGEX-KG and expressed in E. coli SG12036. In vitro: Two human PaCa cell lines (AsPC-1, poorly differentiated; HPAF-2, moderately differentiated) and human endothelial cells (HUVEC) were exposed to increasing concentrations (1 - 10000 ng/ml) of DT-VEGF. Cell proliferation was assessed after 3 days by cell count and MTT-assay. In vivo: 1 mm3 fragments of sc. PaCa donor tumors were implanted into the pancreas of nude mice which received either DT-VEGF (200 µg/kg, every other day) or vehicle (Con) ip. for 14 weeks. Volume of primary tumor (TU-Vol), metastatic spread (Met-Score), and animal weight were determined at autopsy. Microvessel density (MVD) was analyzed in CD31-stained tumor sections.

Results: In vitro: Proliferation of the PaCa cells was significantly inhibited at high concentrations of DT-VEGF ( 1000 ng/ml). In contrast, DT-VEGF effectively decreased the growth of HUVEC at 10 ng/ml. In vivo: Table (p<0.05 vs. Con).

Conclusions: DT-VEGF fusion protein reduced tumor growth and metastatic spread of PaCa in vivo, resulting in increased survival of the animals. In vitro data and reduced MVD indicate that this effect was due to the toxic effect of DT-VEGF on endothelial cells of the tumor vasculature rather than to direct inhibition of PaCa cell growth. DT-VEGF therapy was not associated with systemic side effects such as weight loss.



TU-Vol. (mm3) 1386±155 652±73* 3920±495 927±122*

Met-Score (pts) 16.5±1.3 8.3±1.1* 7.2±1.3 0.75±0.16*

Survival (n/n) 1 / 8 6 / 8* 4 / 8 7 / 8

Weight (gram) 28.2±0.8 27.3±0.9 30.0±0.7 29.6±1.3

MVD /0.74 mm2 69.8±5.1 26.6±3.8* 85.7±7.2 39.6±4.3*

Society for Surgery of the Alimentary Tract

Facebook Twitter YouTube

Email SSAT Email SSAT
500 Cummings Center, Suite 4400, Beverly, MA 01915 500 Cummings Center
Suite 4400
Beverly, MA 01915
+1 978-927-8330 +1 978-927-8330
+1 978-524-0498 +1 978-524-0498
Annual Meeting
Job Board
Make a Pledge
Event Calendar